Combined Solution Set Addresses Critical Hurdles in Bringing Gene Therapy Products to IND

组合解决方案集解决了将基因治疗产品引入IND的关键障碍

DALLAS, TX / ACCESSWIRE / February 28, 2024 / Form Bio, the breakthrough computational life sciences solutions provider, and Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, today announced a new partnership to provide a complete and holistic solution offering for AAV gene therapy design and development.

德克萨斯州达拉斯/ACCESSWIRE/2024年2月28日/Form Bio，突破性的计算生命科学解决方案提供商，以及正在构建细胞编程和生物安全领先平台的Ginkgo Bioworks，今天宣布建立新的合作伙伴关系，为AAV基因治疗的设计和开发提供完整的整体解决方案。

The combined offering marries the power of Ginkgo's licensable assets, cell lines and foundry capabilities with Form's award-winning in silico solutions for characterization, simulation and AI-enabled construct design optimization..

该组合产品将银杏的可授权资产、细胞系和铸造能力与Form屡获殊荣的表征、模拟和人工智能结构设计优化计算机解决方案相结合。。

The new, combined solution provides one-stop shopping for gene therapy developers looking to optimize their products while reducing time-to-clinic and conserving capital. With the new end-to-end capabilities, gene therapy developers now have a new way to reduce time and development costs while developing products that aim to achieve safer, more effective and more scalable outcomes..

新的组合解决方案为寻求优化产品的基因治疗开发人员提供了一站式购物，同时减少了临床时间并节省了资金。凭借新的端到端功能，基因治疗开发人员现在有了一种新的方法来减少时间和开发成本，同时开发旨在实现更安全，更有效和更可扩展结果的产品。。

'We are now seeing that AI can reduce preclinical development time by over 30 percent, offering the potential to get life-saving treatments to patients faster and at lower costs,' said Kent Wakeford, co-founder and co-chief executive officer for Form Bio. 'By combining AI and integrated manufacturing modeling with Ginkgo's industry-leading AAV products and services, our clients can get virtually everything they need for accelerated AAV therapeutic development in one integrated solution,' he added..

Form Bio联合创始人兼联合首席执行官肯特·韦克福德（Kent Wakeford）说：“我们现在看到，人工智能可以将临床前开发时间缩短30%以上，从而有可能以更快的速度和更低的成本为患者提供救生治疗。通过将人工智能和集成制造建模与银杏行业领先的AAV产品和服务相结合，他补充说：“我们的客户几乎可以在一个集成解决方案中获得加速AAV治疗开发所需的一切。”。。

Ginkgo's existing suite of capabilities for gene therapy include licensable capsid assets, capsid engineering services, payload engineering and manufacturing optimization services, while Form Bio provides highly complementary in silico solutions ranging from product characterization to immunotoxicity analysis to gene expression prediction and AI-based construct design optimization..

银杏现有的基因治疗能力包括可许可的衣壳资产、衣壳工程服务、有效载荷工程和制造优化服务，而Form Bio提供高度互补的计算机解决方案，从产品表征到免疫毒性分析，再到基因表达预测和基于AI的构建体设计优化。。

'We're very excited to have Form Bio as an inaugural partner in our Technology Network. Form Bio is a pioneer in applying AI and innovative in silico techniques to AAV development, transforming how gene therapies are developed,' said Jason Kelly, co-founder and Chief Executive Officer of Ginkgo Bioworks.

银杏生物工程（Ginkgo Bioworks）联合创始人兼首席执行官杰森·凯利（JasonKelly）说：“我们很高兴能有Form Bio作为我们技术网络的第一合作伙伴。Form Bio是将人工智能和创新的计算机技术应用于AAV开发的先驱，改变了基因疗法的开发方式。”。

'We are excited by the value that this collaboration will provide to our customers, who are looking for ways to leverage the advances in generative AI in a fully integrated manner,' he added..

他补充道：“我们对此次合作将为我们的客户提供的价值感到兴奋，他们正在寻找以完全集成的方式利用生成人工智能的进步的方法。”。。

The two companies are teaming on gene therapy specifically today, although both offer broad capabilities across nucleic acids, delivery platforms and therapeutic modalities.

尽管两家公司都提供了跨越核酸、递送平台和治疗方式的广泛功能，但它们目前正在专门合作进行基因治疗。

There are more than 2,000 gene therapies currently in development according to ASGCT and Citeline's Gene, Cell, + RNA Therapy Landscape Report for Q4 2023. But there are significant challenges involved in designing therapeutic products that are simultaneously safe enough, effective enough and manufacturable enough to reach the clinic and the patients afflicted by targeted indications..

根据ASGCT和Citeline 2023年第四季度的基因、细胞和+RNA治疗前景报告，目前正在开发2000多种基因疗法。但是，在设计同时足够安全、有效和可制造的治疗产品以到达诊所和受靶向适应症困扰的患者方面，存在重大挑战。。

About Form Bio

关于Form Bio

Form Bio provides award-winning software and AI solutions for cell and gene therapy leaders. By combining data, technology and expertise, Form's solutions accelerate timelines from discovery to clinic by providing drug developers with rapid in silico characterization, prediction, simulation and optimization of their therapeutics - enabling higher yields, enhanced safety and shorter, less-expensive development cycles.

Form Bio为细胞和基因治疗领导者提供屡获殊荣的软件和AI解决方案。通过结合数据、技术和专业知识，Form的解决方案为药物开发人员提供了快速的计算机表征、预测、模拟和优化治疗方法，从而加快了从发现到临床的时间表，从而实现了更高的产量、更高的安全性和更短、更便宜的开发周期。

With cross-disciplinary expertise spanning software engineering, biology, bioinformatics and data science, the Form Bio team collaborates closely with customers on their most pressing and strategic challenges and opportunities. For more information, visit www.formbio.com or follow the company at https://www.linkedin.com/company/formbio..

凭借跨越软件工程、生物学、生物信息学和数据科学的跨学科专业知识，Form Bio团队在客户最紧迫和战略性的挑战和机遇上与客户密切合作。欲了解更多信息，请访问www.formbio.com或关注公司https://www.linkedin.com/company/formbio..

About Ginkgo Bioworks

关于银杏生物制品

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats.

银杏生物工程（Ginkgo Bioworks）是细胞编程的领先水平平台，提供灵活的端到端服务，为食品和农业、制药、工业和特种化学品等不同市场的组织解决挑战。银杏的生物安全和公共卫生部门由银杏同心，正在建设全球生物安全基础设施，以增强政府、社区和公共卫生领导人预防、检测和应对各种生物威胁的能力。

For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read our blog or follow us on social media channels such as X (formerly known as Twitter) (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) or LinkedIn..

有关更多信息，请访问ginkgobioworks.com和concentricbygingo.com，阅读我们的博客或通过社交媒体渠道关注我们，例如X（以前称为Twitter）（@gingo和@ConcentricByGBW）、Instagram（@ginkgobioworks）、Threads（@ginkgobioworks）或LinkedIn。。

Forward-Looking Statements of Ginkgo Bioworks

银杏生物制品的前瞻性陈述

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the Technology Partnership and Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words 'believe,' 'can,' 'project,' 'potential,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'strategy,' 'future,' 'opportunity,' 'plan,' 'may,' 'should,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions.

本新闻稿包含联邦证券法所指的某些前瞻性声明，包括关于技术合作伙伴关系和银杏细胞编程平台的能力和潜在成功的声明。这些前瞻性陈述通常由“相信”、“可以”、“项目”、“潜力”、“期望”、“预期”、“估计”、“打算”、“战略”、“未来”、“机会”、“计划”、“可能”、“应该”、“将会”、“将会”、“将会”、“将会继续”、“可能的结果”以及类似的表述来识别。

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) our ability to realize the expected benefits of merger and acquisi.

前瞻性陈述是基于当前预期和假设的关于未来事件的预测、预测和其他陈述，因此会受到风险和不确定性的影响。许多因素可能导致实际的未来事件与本新闻稿中的前瞻性声明存在重大差异，包括但不限于：（i）由于各种因素，包括银杏经营和计划经营的竞争性和高度监管行业的变化，竞争对手业绩的变化，银杏证券价格的波动，以及影响银杏业务的法律法规的变化，（ii）实施商业计划、预测和其他期望的能力，以及识别和实现额外商业机会的能力，（iii）使用合成生物学的产品需求下降的风险，（iv）被动监测计划和生物安全服务需求的不确定性，（v）生物安全行业的变化，包括技术进步、新兴竞争以及行业需求、标准和法规的演变，（vi）我们实现并购预期收益的能力。

Contact Information

联系方式

Angela Anderson

安吉拉·安德森

Form Bio

表格Bio

angela@formbio.com

angela@formbio.com

Jake Robison

杰克·罗宾逊

Inizio Evoke Comms

启动Evoke通信

jake.robison@inizioevoke.com

jake.robison@inizioevoke.com

SOURCE: Form Bio

来源：Form Bio

View the original press release on newswire.com.

在newswire.com上查看原始新闻稿。